The Europe Dystonia Drugs Market should witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Two or more contiguous or close-proximity body parts are affected by segmental dystonia. Up to 30% of individuals with focal dystonia experience spasms in regions close to the primary location. A prevalent form of segmental dystonia affects the lower face, jaw, and eyelids. Different varieties of dystonia include multifocal, which involves two or more distant body parts, and hemidystonia, which affects half the body. And generalized, which typically begins in the legs and then extends to one or more body areas.
Primary (idiopathic) dystonia is the only symptom, and other causes have been ruled out. Most primary dystonia are varied, manifest in adults, and are focal or segmental in origin. Yet, specific childhood or adolescent-onset primary dystonia have been associated with genetic alterations. DYT1 gene mutations cause most childhood or early adulthood-onset primary dystonia. This gene has been located at 9q34.1 on the long arm of chromosome 9. In 90 to 95% of cases, symptoms begin in a limb before spreading to other body areas. This dystonia typically manifests itself between the ages of 12 and 29.
Germany's healthcare system is robust in terms of facilities, hospital beds, and qualified personnel. In Germany, one in six employees is related to the healthcare industry, which has an economic impact of EUR 678.2 billion (USD 798 billion), or nearly 12% of Germany's GDP. HCT contributes 8.3% of Germany's overall exports, or EUR 131.2 billion (USD 154.4 billion), through foreign sales. The German medical equipment industry will grow at a compound annual growth rateof 5.1 percent in euro terms and 6.8 percent in US dollar terms between 2020 and 2025. The presence of a robust healthcare system, joined with the increased spending, will aid in the development of dystonia drugs and their usage thereby driving the market growth in the Europe region.
The Germany market dominated the Europe Dystonia Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $77.3 Million by 2028. The UK market is anticipated to grow at a CAGR of 4.3% during (2022-2028). Additionally, The France market would exhibit a CAGR of 6% during (2022-2028).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Type, the market is segmented into GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.
Two or more contiguous or close-proximity body parts are affected by segmental dystonia. Up to 30% of individuals with focal dystonia experience spasms in regions close to the primary location. A prevalent form of segmental dystonia affects the lower face, jaw, and eyelids. Different varieties of dystonia include multifocal, which involves two or more distant body parts, and hemidystonia, which affects half the body. And generalized, which typically begins in the legs and then extends to one or more body areas.
Primary (idiopathic) dystonia is the only symptom, and other causes have been ruled out. Most primary dystonia are varied, manifest in adults, and are focal or segmental in origin. Yet, specific childhood or adolescent-onset primary dystonia have been associated with genetic alterations. DYT1 gene mutations cause most childhood or early adulthood-onset primary dystonia. This gene has been located at 9q34.1 on the long arm of chromosome 9. In 90 to 95% of cases, symptoms begin in a limb before spreading to other body areas. This dystonia typically manifests itself between the ages of 12 and 29.
Germany's healthcare system is robust in terms of facilities, hospital beds, and qualified personnel. In Germany, one in six employees is related to the healthcare industry, which has an economic impact of EUR 678.2 billion (USD 798 billion), or nearly 12% of Germany's GDP. HCT contributes 8.3% of Germany's overall exports, or EUR 131.2 billion (USD 154.4 billion), through foreign sales. The German medical equipment industry will grow at a compound annual growth rateof 5.1 percent in euro terms and 6.8 percent in US dollar terms between 2020 and 2025. The presence of a robust healthcare system, joined with the increased spending, will aid in the development of dystonia drugs and their usage thereby driving the market growth in the Europe region.
The Germany market dominated the Europe Dystonia Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $77.3 Million by 2028. The UK market is anticipated to grow at a CAGR of 4.3% during (2022-2028). Additionally, The France market would exhibit a CAGR of 6% during (2022-2028).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Type, the market is segmented into GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.
Scope of the Study
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Route of Administration
- Oral
- Injectable
By Type
- GABAergic Agents
- Dopaminergic Agents
- Anticonvulsants Drugs
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- F.Hoffmann-La Roche Ltd.
- Ipsen Pharma Biotech SAS
- Hameln Pharma Gmbh (Siegfried Group, LLP)
- Amneal Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KGaA
- Wellona Pharma
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Dystonia Drugs Market, by Distribution Channel
1.4.2 Europe Dystonia Drugs Market, by Route of Administration
1.4.3 Europe Dystonia Drugs Market, by Type
1.4.4 Europe Dystonia Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Dystonia Drugs Market by Distribution Channel
3.1 Europe Drug Stores & Retail Pharmacies Market by Country
3.2 Europe Hospital Pharmacies Market by Country
3.3 Europe Online Providers Market by Country
Chapter 4. Europe Dystonia Drugs Market by Route of Administration
4.1 Europe Oral Market by Country
4.2 Europe Injectable Market by Country
Chapter 5. Europe Dystonia Drugs Market by Type
5.1 Europe GABAergic Agents Market by Country
5.2 Europe Dopaminergic Agents Market by Country
5.3 Europe Anticonvulsants Drugs Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Dystonia Drugs Market by Country
6.1 Germany Dystonia Drugs Market
6.1.1 Germany Dystonia Drugs Market by Distribution Channel
6.1.2 Germany Dystonia Drugs Market by Route of Administration
6.1.3 Germany Dystonia Drugs Market by Type
6.2 UK Dystonia Drugs Market
6.2.1 UK Dystonia Drugs Market by Distribution Channel
6.2.2 UK Dystonia Drugs Market by Route of Administration
6.2.3 UK Dystonia Drugs Market by Type
6.3 France Dystonia Drugs Market
6.3.1 France Dystonia Drugs Market by Distribution Channel
6.3.2 France Dystonia Drugs Market by Route of Administration
6.3.3 France Dystonia Drugs Market by Type
6.4 Russia Dystonia Drugs Market
6.4.1 Russia Dystonia Drugs Market by Distribution Channel
6.4.2 Russia Dystonia Drugs Market by Route of Administration
6.4.3 Russia Dystonia Drugs Market by Type
6.5 Spain Dystonia Drugs Market
6.5.1 Spain Dystonia Drugs Market by Distribution Channel
6.5.2 Spain Dystonia Drugs Market by Route of Administration
6.5.3 Spain Dystonia Drugs Market by Type
6.6 Italy Dystonia Drugs Market
6.6.1 Italy Dystonia Drugs Market by Distribution Channel
6.6.2 Italy Dystonia Drugs Market by Route of Administration
6.6.3 Italy Dystonia Drugs Market by Type
6.7 Rest of Europe Dystonia Drugs Market
6.7.1 Rest of Europe Dystonia Drugs Market by Distribution Channel
6.7.2 Rest of Europe Dystonia Drugs Market by Route of Administration
6.7.3 Rest of Europe Dystonia Drugs Market by Type
Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Teva Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.4 AbbVie, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Ipsen Pharma Biotech SAS
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Hameln Pharma Gmbh (Siegfried Group, LLP)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.8 Amneal Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expenses
7.9 Merz Pharma GmbH & Co. KGaA
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.10. Wellona Pharma
7.10.1 Company Overview
Companies Mentioned
- Pfizer, Inc.
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Ipsen Pharma Biotech SAS
- Hameln Pharma Gmbh (Siegfried Group, LLP)
- Amneal Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KGaA
- Wellona Pharma
Methodology
LOADING...
